전체 프로그램

ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved36 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

AntibodyCurated CoreFDAstaleRocheApproved

bevacizumab (Avastin)

US label: colorectal, non-squamous NSCLC, glioblastoma, renal, cervical and ovarian cancers; regimen-specific indicatio… · VEGF-A

#VEGF-A#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 1444Status Approved
AntibodyCurated CoreFDAstaleRocheApproved

rituximab (Rituxan)

US label: non-Hodgkin lymphoma, CLL, rheumatoid arthritis, GPA/MPA and pemphigus vulgaris; population-specific indicati… · CD20

#CD20#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 1337Status Approved
AntibodyCurated CoreFDAstaleBristol Myers SquibbApproved

nivolumab (Opdivo, BMS-936558)

Melanoma, NSCLC, RCC, HCC, MSI-H tumors, and others · PD-1

#PD-1#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 1280Status Approved
AntibodyCurated CoreFDAstaleEli LillyApproved

cetuximab (Erbitux)

US label: head and neck squamous cell cancer and biomarker-selected colorectal cancer; regimen-specific indications · EGFR

#EGFR#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 942Status Approved
AntibodyCurated CoreFDAstaleSanofiApproved

dupilumab (Dupixent, REGN668)

Atopic dermatitis, asthma, CRSwNP, EoE, prurigo nodularis · IL-4Rα

#IL-4R#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 278Status Approved
ADCCurated CoreFDAstaleDaiichi SankyoDXd (topo-I inhibitor)Approved

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, TDxd)

HER2-positive breast cancer (including regimen-specific first-line and early-stage indications); HER2-low/ultralow brea… · HER2

#HER2#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 243Status Approved
ADCCurated CoreFDAstaleGileadSN-38 (topoisomerase I inhi…Approved

sacituzumab govitecan-hziy (Trodelvy, IMMU-132, sacituzumab-govitecan-hziy)

TNBC: regimen-specific first-line and previously treated indications; HR-positive/HER2-negative breast cancer after spe… · TROP2

#TROP2#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 242Status Approved
AntibodyCurated CoreFDAstaleAmgenApproved

etanercept (Enbrel, TNFR-Fc)

RA, PsA, AS, plaque psoriasis, JIA · TNF (decoy receptor)

#TNFdecoyreceptor#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 236Status Approved
ADCCurated CoreFDAstaleAstellasMMAE (monomethyl auristatin…Approved

enfortumab vedotin-ejfv (Padcev, ASG-22ME, enfortumab-vedotin-ejfv)

Locally advanced or metastatic urothelial carcinoma · Nectin-4

#Nectin-4#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 201Status Approved
AntibodyCurated CoreFDAstaleJohnson & JohnsonApproved

ustekinumab (Stelara, Wezlana)

Psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis · IL-12 / IL-23 (p40)

#IL-12IL-23p40#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 195Status Approved
ADCCurated CoreFDAstaleRocheDM1 (maytansine derivative)Approved

ado-trastuzumab emtansine (Kadcyla, T-DM1, Trastuzumab Emtansine)

HER2+ breast cancer · HER2

#HER2#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 186Status Approved
AntibodyCurated CoreFDAstaleJohnson & JohnsonApproved

teclistamab-cqyv (Tecvayli, JNJ-64007957, teclistamab)

Relapsed or refractory multiple myeloma · BCMA × CD3

#BCMACD3#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 132Status Approved
AntibodyCurated CoreFDAstaleAbbVieApproved

risankizumab-rzaa (Skyrizi, BI 655066, risankizumab)

Plaque psoriasis, PsA, Crohn's disease, ulcerative colitis · IL-23 p19

#IL-23p19#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 110Status Approved
ADCCurated CoreFDAstaleRochevedotin, rituximab, cycloph…Phase 3

Polatuzumab Vedotin (Polatuzumab Vedotin)

Large B-Cell Lymphoma · FRα

#FR#ADC#Phase3#FDA-approved#BioJungboMoa-pick+5
Trials 91Status Recruiting
AntibodyCurated CoreFDAstaleRocheApproved

glofitamab (Columvi, RO7082859, glofitamab-gxbm)

Relapsed or refractory diffuse large B-cell lymphoma · CD20 × CD3

#CD20CD3#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 90Status Approved
AntibodyCurated CoreFDAstaleJohnson & JohnsonApproved

guselkumab (Tremfya, CNTO 1959)

Plaque psoriasis, psoriatic arthritis, ulcerative colitis, Crohn's disease · IL-23 p19

#IL-23p19#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 87Status Approved
ADCCurated CoreFDAstaleGSKMMAFApproved

belantamab mafodotin (Blenrep, GSK2857916)

Multiple myeloma · BCMA

#BCMA#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 78Status Discontinued
AntibodyCurated CoreFDAstaleUCBApproved

bimekizumab (Bimzelx, UCB4940, bimekizumab-bkzx)

Plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa · IL-17A / IL-17F

#IL-17AIL-17F#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 58Status Approved
AntibodyCurated CoreFDAstaleGenmabApproved

epcoritamab (Epkinly, GEN3013, Tepkinly, epcoritamab-bysp)

Relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma · CD20 × CD3

#CD20CD3#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 57Status Approved
AntibodyCurated CoreFDAstaleRocheApproved

faricimab (Vabysmo, RG7716, faricimab-svoa)

Wet AMD, diabetic macular edema, macular edema following retinal vein occlusion · Ang-2 / VEGF-A

#Ang-2VEGF-A#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 53Status Approved

1 / 2 pages

← PreviousNext →